Sarepta Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 5, 2020 and accepted by EDGAR at Aug 5, 2020, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $111.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $211.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 3 months2020-04-01 to 2020-06-30 | $73.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2020-01-01 to 2020-06-30 | $156.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$138.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$256.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-04-01 to 2020-06-30 | $13.7m | us-gaap:InterestExpense |
| Interest expense | 6 months2020-01-01 to 2020-06-30 | $27.3m | us-gaap:InterestExpense |
| Income tax | 3 months2020-04-01 to 2020-06-30 | $20.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | $135.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$150.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$168.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | −$1.93 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | −$2.18 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 77,968,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-01-01 to 2020-06-30 | 77,200,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | $520.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $28.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $1.64bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $2.46bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $2.88bn | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $354.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $1.84bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $1.04bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-036794. Last ingested by Listed: Nov 14, 2026, 19:58 ET. Listed shows no prices and gives no investment advice.